Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab + Platinum-Based Salvage Chemotherapy in R/R Aggressive B Cell Lymphoma
NCT05464329Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2023
- Primary completion
- Jan 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of mosunetuzumab in B cell lymphoma (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Frequencies and grades of treatment-emergent adverse events at 16 weeks and Rate of treatment delay or discontinuation due to treatment-emergent adverse events at 12 weeks. Started Jan 2023; status: active, not recruiting.
02
Drugs
mosunetuzumab
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT05464329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05464329.